{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:09:08Z","timestamp":1784621348287,"version":"3.55.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Motivation<\/jats:title>\n                  <jats:p>Val600Glu (V600E) mutation is the most common BRAF mutation detected in thyroid cancer. Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions. Among them, vemurafenib is a selective BRAF inhibitor approved by Food and Drug Administration for clinical practice. Unfortunately, vemurafenib often displays limited efficacy in poorly differentiated and anaplastic thyroid carcinomas probably because of intrinsic and\/or acquired resistance mechanisms. In this view, cancer stem cells (CSCs) may represent a possible mechanism of resistance to vemurafenib, due to their self-renewal and chemo resistance properties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We present a computational framework to suggest new potential targets to overcome drug resistance. It has been validated with an in\u00a0vitro model based upon a spheroid-forming method able to isolate thyroid CSCs that may mimic resistance to vemurafenib. Indeed, vemurafenib did not inhibit cell proliferation of BRAF V600E thyroid CSCs, but rather stimulated cell proliferation along with a paradoxical over-activation of ERK and AKT pathways. The computational model identified a fundamental role of mitogen-activated protein kinase 8 (MAP3K8), a serine\/threonine kinase expressed in thyroid CSCs, in mediating this drug resistance. To confirm model prediction, we set a suitable in\u00a0vitro experiment revealing that the treatment with MAP3K8 inhibitor restored the effect of vemurafenib in terms of both DNA fragmentation and poly (ADP-ribose) polymerase cleavage (apoptosis) in thyroid CSCs. Moreover, MAP3K8 expression levels may be a useful marker to predict the response to vemurafenib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Availability and implementation<\/jats:title>\n                  <jats:p>The model is available in GitHub repository visiting the following URL: https:\/\/github.com\/francescopappalardo\/MAP3K8-Thyroid-Spheres-V-3.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Supplementary information<\/jats:title>\n                  <jats:p>Supplementary data are available at Bioinformatics online.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bioinformatics\/bty969","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T20:27:23Z","timestamp":1543264043000},"page":"2267-2275","source":"Crossref","is-referenced-by-count":26,"title":["Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells"],"prefix":"10.1093","volume":"35","author":[{"given":"Fiorenza","family":"Gian\u00ec","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular BioMedicine, Garibaldi-Nesima Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzio","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sciacca","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular BioMedicine, Garibaldi-Nesima Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frasca","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular BioMedicine, Garibaldi-Nesima Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[{"name":"Department of Drug Sciences, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"2023051612114420100_bty969-B1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jc.2013-2558","article-title":"Detection of thyroid cancer stem cells in papillary thyroid carcinoma","volume":"99","author":"Ahn","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2023051612114420100_bty969-B2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2023051612114420100_bty969-B3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbrc.2011.12.051","article-title":"About and beyond the Henri-Michaelis\u2013Menten rate equation for single-substrate enzyme kinetics","volume":"417","author":"Bajzer","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2023051612114420100_bty969-B4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/modpathol.3800198","article-title":"BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment","volume":"17","author":"Begum","year":"2004","journal-title":"Mod. Pathol."},{"key":"2023051612114420100_bty969-B5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2265.2005.02401.x","article-title":"Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins)","volume":"64","author":"Carta","year":"2006","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2023051612114420100_bty969-B6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI23237","article-title":"Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer","volume":"115","author":"Ciampi","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2023051612114420100_bty969-B7","volume-title":"Introduction to Algorithms\u2013Instructor\u2019s Manual to Accompany","author":"Cormen","year":"2002","edition":"2"},{"key":"2023051612114420100_bty969-B8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E)mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocr. Relat. Cancer."},{"key":"2023051612114420100_bty969-B9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/cr.2010.173","article-title":"Regulation and function of TPL-2, an I\u03baB kinase-regulated MAP kinase kinase kinase","volume":"21","author":"Gantke","year":"2011","journal-title":"Cell Res."},{"key":"2023051612114420100_bty969-B10","doi-asserted-by":"crossref","first-page":"E1168","DOI":"10.1210\/jc.2014-4163","article-title":"Thyrospheres from normal or malignant thyroid tissue have different biological, functional, and genetic features","volume":"100","author":"Gian\u00ec","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2023051612114420100_bty969-B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.physchem.58.032806.104637","article-title":"Stochastic simulation of chemical kinetics","volume":"58","author":"Gillespie","year":"2007","journal-title":"Annu. Rev. Phys. Chem."},{"key":"2023051612114420100_bty969-B12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3892\/ol.2016.4666","article-title":"Resistance of papillary thyroid cancer stem cells to chemotherapy","volume":"12","author":"Giuffrida","year":"2016","journal-title":"Oncol. Lett."},{"key":"2023051612114420100_bty969-B13","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1038\/ncomms9583","article-title":"MAP3K8\/TPL-2\/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas","volume":"6","author":"Gruosso","year":"2015","journal-title":"Nat. Commun."},{"key":"2023051612114420100_bty969-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4161\/cc.6.3.3818","article-title":"Functional characterization of the T1799\u20131801del and G1799\u20131816ins BRAF mutations in papillary thyroid cancer","volume":"6","author":"Hou","year":"2007","journal-title":"Cell Cycle"},{"key":"2023051612114420100_bty969-B15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2023051612114420100_bty969-B16","doi-asserted-by":"crossref","first-page":"e16205","DOI":"10.1371\/journal.pone.0016205","article-title":"TPL2\/COT\/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth","volume":"6","author":"Jeong","year":"2011","journal-title":"PLoS One"},{"key":"2023051612114420100_bty969-B17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"2023051612114420100_bty969-B18","doi-asserted-by":"crossref","first-page":"D277","DOI":"10.1093\/nar\/gkh063","article-title":"The KEGG resource for deciphering the genome","volume":"32","author":"Kanehisa","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"2023051612114420100_bty969-B19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/carcin\/bgu044","article-title":"Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation","volume":"35","author":"Kim","year":"2014","journal-title":"Carcinogenesis"},{"key":"2023051612114420100_bty969-B20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","article-title":"Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets","volume":"21","author":"Knauf","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"2023051612114420100_bty969-B21","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.3390\/ijms16034471","article-title":"Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer","volume":"16","author":"Lee","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"2023051612114420100_bty969-B22","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/ijc.29248","article-title":"Tpl2 induces castration resistant prostate cancer progression and metastasis","volume":"136","author":"Lee","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2023051612114420100_bty969-B23","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1097\/MD.0000000000000548","article-title":"Aberrant expression of COT is related to recurrence of papillary thyroid cancer","volume":"94","author":"Lee","year":"2015","journal-title":"Med. (Baltimore)"},{"key":"2023051612114420100_bty969-B24","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/0008-5472.CAN-15-3274","article-title":"TPL2 is an oncogenic driver in keratocanthoma and squamous cell carcinoma","volume":"76","author":"Lee","year":"2016","journal-title":"Cancer Res."},{"key":"2023051612114420100_bty969-B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/msb.2008.29","article-title":"Recurrent design patterns in the feedback regulation of the mammalian signalling network","volume":"4","author":"Legewie","year":"2008","journal-title":"Mol. Syst. Biol."},{"key":"2023051612114420100_bty969-B26","doi-asserted-by":"crossref","first-page":"e65095","DOI":"10.1371\/journal.pone.0065095","article-title":"Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"2023051612114420100_bty969-B27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/stem.2492","article-title":"Interleukin-8, but not the related chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells","volume":"35","author":"Liotti","year":"2017","journal-title":"Stem Cells"},{"key":"2023051612114420100_bty969-B28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/jc.2010-1255","article-title":"Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid","volume":"96","author":"Malaguarnera","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2023051612114420100_bty969-B29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biocel.2014.02.002","article-title":"TPL2 signalling: from toll-like receptors-mediated ERK1\/ERK2 activation to cystic fibrosis lung disease","volume":"52","author":"Martel","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2023051612114420100_bty969-B30","first-page":"17","article-title":"Computational modeling of biochemical networks using COPASI","volume-title":"Systems Biology. Methods in Molecular Biology (Methods and Protocols)","author":"Mendes","year":"2009"},{"key":"2023051612114420100_bty969-B31","first-page":"4088","article-title":"Structure and transforming potential of the human cot oncogene encoding a putative protein kinase","volume":"11","author":"Miyoshi","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"2023051612114420100_bty969-B32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"2023051612114420100_bty969-B33","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2023051612114420100_bty969-B34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.chemolab.2016.03.015","article-title":"Computational study on the drug resistance mechanism of hepatitis C virus NS5B RNA-dependent RNA polymerase mutants to BMS-791325 by molecular dynamics simulation and binding free energy calculations","volume":"154","author":"Pan","year":"2016","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"2023051612114420100_bty969-B35","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1042\/BCJ20160502","article-title":"TLR and TNF-R1 activation of the MKK3\/MKK6-p38 axis in macrophages is mediated by TPL-2 kinase","volume":"473","author":"Pattison","year":"2016","journal-title":"Biochem. J."},{"key":"2023051612114420100_bty969-B36","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1089\/thy.2014.0014","article-title":"Bioluminescent human thyrospheres allow noninvasive detection of anaplastic thyroid cancer growth and metastases in\u00a0vivo","volume":"24","author":"Reeb","year":"2014","journal-title":"Thyroid"},{"key":"2023051612114420100_bty969-B37","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1038\/sj.onc.1202891","article-title":"Overexpression of the Tpl-2\/Cot oncogene in human breast cancer","volume":"18","author":"Sourvinos","year":"1999","journal-title":"Oncogene"},{"key":"2023051612114420100_bty969-B38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/bib\/bbx065","article-title":"Mathematical modeling and computational prediction of cancer drug resistance","volume":"19","author":"Sun","year":"2018","journal-title":"Brief. Bioinform."},{"key":"2023051612114420100_bty969-B39","doi-asserted-by":"crossref","first-page":"8874","DOI":"10.1158\/0008-5472.CAN-10-1994","article-title":"Tumorigenic and metastatic activity of human thyroid cancer stem cells","volume":"70","author":"Todaro","year":"2010","journal-title":"Cancer Res."},{"key":"2023051612114420100_bty969-B40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2006.03.013","article-title":"B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas","volume":"37","author":"Trovisco","year":"2006","journal-title":"Hum. Pathol."},{"key":"2023051612114420100_bty969-B41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2011.02.004","article-title":"Tpl2 kinase signal transduction in inflammation and cancer","volume":"304","author":"Vougioukalaki","year":"2011","journal-title":"Cancer Lett."},{"key":"2023051612114420100_bty969-B42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"2023051612114420100_bty969-B43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","article-title":"Clinical pharmacokinetics of vemurafenib","volume":"56","author":"Zhang","year":"2017","journal-title":"Clin. Pharmacokinet."}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/35\/13\/2267\/50340391\/bioinformatics_35_13_2267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/35\/13\/2267\/50340391\/bioinformatics_35_13_2267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T12:12:33Z","timestamp":1684239153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/35\/13\/2267\/5210872"}},"subtitle":[],"editor":[{"given":"Russell","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/bty969","relation":{},"ISSN":["1367-4803","1367-4811"],"issn-type":[{"value":"1367-4803","type":"print"},{"value":"1367-4811","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2018,11,27]]}}}